Bluejay Diagnostics Director Increases Personal Stake Following Recent Corporate Activity

Bluejay Diagnostics, Inc. (NASDAQ:BJDX), is demonstrating continuous corporate activity, highlighted by a recent increase in personal holdings by one of its directors. Douglas Clark Wurth, a director at Bluejay Diagnostics, recently acquired an additional stake in the company through a direct purchase of common stock.

Specifically, on March 14, 2026, Mr. Wurth purchased 12,500 shares of Bluejay Diagnostics common stock. The acquisition was executed at a price point of $2.00 per share, resulting in a total investment value of $25,000. These shares were obtained through a private placement directly from the issuer.

This insider transaction occurred while the company's stock was trading near levels that reflected significant recent declines. At the time of this purchase, the stock traded at $1.72, which is noted as being close to its 52-week low of $1.65. Furthermore, the reporting indicates that shares have experienced a decline of 77% over the past year.

Following this specific acquisition, Mr. Wurth's direct personal holdings in Bluejay Diagnostics common stock increased to 12,608 shares. This total count includes an additional 34 shares that are held indirectly through Wurth Holdings LLC, an entity controlled by him.

The recent individual purchase is set against a backdrop of substantial corporate financial and strategic developments at Bluejay Diagnostics. In parallel news, the company successfully completed another private placement. This transaction generated $125,000 from the sale of 62,500 shares, with the selling price maintained at $2.00 per share.

The participation in this second private placement was notable as it involved several board members, including CEO Neil Dey and Chair Donald Chase. Both individuals acquired a stake of 12,500 shares through this mechanism.

Beyond the recent placements, Bluejay Diagnostics also finalized the full exercise of prefunded warrants originating from its October 2025 private placement. This action ensured that there were no outstanding warrants remaining as of February 19th. The completion of this warrant exercise resulted in approximately 972,000 shares of common stock becoming outstanding.

Furthermore, the company's ongoing communications and financial status remained active. On March 13th, Bluejay Diagnostics issued a response letter to NorthStrive Fund II LP. This followed an earlier correspondence received from the fund on March 11th. While the specific details of this exchange were not disclosed, the response was included as an exhibit within a recent filing with the SEC.

Key Points and Market Impact

Several key points emerged regarding Bluejay Diagnostics' financial structure and internal confidence:

• Insider Buying Activity: The purchase by Director Wurth suggests continued belief in the company despite depressed stock levels. This activity is generally viewed as an indicator of management or director conviction, potentially affecting investor sentiment within the biotech sector.
• Capital Raising Through Placements: The completion of multiple private placements, including the recent $125,000 raise, demonstrates the company's ability to secure capital from its board members and other investors. This continuous need for funding is a common characteristic in development-stage life science companies.
• Share Structure Changes: The full exercise of prefunded warrants resulted in a significant increase in outstanding shares (approximately 972,000). Such changes directly impact the per-share valuation metrics and overall equity structure of the company.

The actions detailed here are particularly relevant to the